Document is current
Any future updates will be listed below
-
Authors
Maza, Nycole
Wang, Dandan
Kowalski, Cody
Stoveken, Hannah M.
Dao, Maria
Sial, Omar K.
Giles, Andrew C.
Grill, Brock https://orcid.org/0000-0002-0379-3267
Martemyanov, Kirill A. https://orcid.org/0000-0002-9925-7599
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA047771, DA04006, DA048036, DA04006, DA048036, DA036596)
U.S. Department of Health & Human Services | NIH | National Eye Institute (EY028033)
- License Information
-
More Information
Article History
Received: 27 April 2021
Accepted: 11 July 2022
First Online: 18 August 2022
Competing interests
: B.G. and K.A.M. have filed a patent on the utility of Ptchd1 and modulation of neuronal cholesterol for therapeutic purposes. They are also stockholders in Evodenovo Inc., which has financial interests in intellectual property associated with this study.
